O'Brien Susan相关文献与解析，生知库 | 链接生命科学的每一步

Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study

奥德罗内西他单药治疗CAR-T细胞疗法进展后的复发/难治性弥漫性大B细胞淋巴瘤：ELM-1研究的主要分析

doi:10.1182/blood.2024027044

Topp, Max S; Matasar, Matthew; Allan, John N; Ansell, Stephen M; Barnes, Jeffrey A; Arnason, Jon E; Michot, Jean-Marie; Goldschmidt, Neta; O'Brien, Susan M; Abadi, Uri; Avivi, Irit; Cheng, Yuan; Flink, Dina M; Zhu, Min; Brouwer-Visser, Jurriaan; Chaudhry, Aafia; Mohamed, Hesham; Ambati, Srikanth; Crombie, Jennifer L

Comparative efficacy of Bruton tyrosine kinase inhibitors in high-risk relapsed/refractory CLL: a network meta-analysis

布鲁顿酪氨酸激酶抑制剂在高危复发/难治性慢性淋巴细胞白血病中的疗效比较：一项网络荟萃分析

期刊:Blood Advances

影响因子:7.1

doi:10.1182/bloodadvances.2024014523

Shadman, Mazyar; Brown, Jennifer R; Mohseninejad, Leyla; Yang, Keri; Burnett, Heather; Neupane, Binod; Williams, Rhys; Lamanna, Nicole; O'Brien, Susan M; Tedeschi, Alessandra; Tam, Constantine S

Acquired mutations in patients with relapsed/refractory CLL who progressed in the ALPINE study

ALPINE 研究中复发/难治性 CLL 患者获得性突变

期刊:Blood Advances

影响因子:7.1

doi:10.1182/bloodadvances.2024014206

Brown, Jennifer R; Li, Jessica; Eichhorst, Barbara F; Lamanna, Nicole; O'Brien, Susan M; Tam, Constantine S; Qiu, Lugui; Huang, Ruiqi; Shi, Yang; Idoine, Adam; Salmi, Tommi; Cohen, Aileen Cleary; Shadman, Mazyar

发表日期：2025

文献求助收藏

Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912

E1912 研究中，接受伊布替尼治疗的 CLL 患者中，IGHV 突变状态与耐受性和长期疾病控制之间的关系

期刊:Blood Advances

影响因子:7.1

doi:10.1182/bloodadvances.2024013474

Shanafelt, Tait D; Wang, Xin Victoria; Hanson, Curtis A; Paietta, Elisabeth; O'Brien, Susan; Barrientos, Jacqueline; Jelinek, Diane F; Braggio, Esteban; Leis, Jose F; Zhang, Cong Christine; Barr, Paul M; Cashen, Amanda F; Mato, Anthony R; Singh, Avina K; Mullane, Michael P; Little, Richard F; Erba, Harry; Stone, Richard M; Litzow, Mark; Tallman, Martin; Kay, Neil E

发表日期：2025

文献求助收藏

Real-world survival outcomes in first-line ibrutinib-treated patients with high-risk CLL/SLL

一线接受伊布替尼治疗的高危慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者的真实世界生存结果

期刊:Blood Advances

影响因子:7.1

doi:10.1182/bloodadvances.2024015417

Allan, John N; Ran, Tao; Ding, Zhijie; He, Jinghua; Bokun, Alex; Qureshi, Zaina P; O'Brien, Susan M

Efficacy of zanubrutinib versus acalabrutinib for relapsed or refractory chronic lymphocytic leukemia (R/R CLL): a matching-adjusted indirect comparison (MAIC)

zanubrutinib 与 acalabrutinib 治疗复发或难治性慢性淋巴细胞白血病 (R/R CLL) 的疗效：匹配调整间接比较 (MAIC)

期刊:Therapeutic Advances in Medical Oncology

影响因子:4.2

doi:10.1177/17588359251340554

Shadman, Mazyar; Brown, Jennifer R; Williams, Rhys; Mohseninejad, Leyla; Yang, Keri; Rakonczai, Pal; Lamanna, Nicole; Xu, Sheng; Cleary Cohen, Aileen; O'Brien, Susan M; Tedeschi, Alessandra; Tam, Constantine S

Composite chronic lymphocytic leukemia and mantle cell lymphoma involving the bone marrow: a case report and literature review

累及骨髓的复合型慢性淋巴细胞白血病和套细胞淋巴瘤：病例报告及文献综述

期刊:Journal of Pathology and Translational Medicine

影响因子:3

doi:10.4132/jptm.2025.07.02

Demianets, Roksolana; O'Brien, Susan; Mahdavi, Khosrow; Niu, Chenchen; Aslam, Sumayya; Tran, Truc; Zhang, Ying; Gamayo, Ashley; Zhao, Xiaohui; Rezk, Sherif A

Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE

在复发/难治性慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者中，泽布替尼与伊布替尼的持续获益：ALPINE 研究的最终比较分析

期刊:Blood

影响因子:23.1

doi:10.1182/blood.2024024667

Brown, Jennifer R; Eichhorst, Barbara; Lamanna, Nicole; O'Brien, Susan M; Tam, Constantine S; Qiu, Lugui; Jurczak, Wojciech; Zhou, Keshu; Šimkovič, Martin; Mayer, Jiří; Gillespie-Twardy, Amanda; Ferrajoli, Alessandra; Ganly, Peter S; Weinkove, Robert; Grosicki, Sebastian; Mital, Andrzej; Robak, Tadeusz; Osterborg, Anders; Yimer, Habte A; Wang, Megan; Salmi, Tommi; Wang, Liping; Li, Jessica; Wu, Kenneth; Cohen, Aileen; Shadman, Mazyar

Similar efficacy of ibrutinib arms across ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia: a matching-adjusted indirect comparison

在复发/难治性慢性淋巴细胞白血病的ALPINE和ELEVATE-RR试验中，伊布替尼各组的疗效相似：一项匹配调整的间接比较研究

期刊:Blood Cancer Journal

影响因子:11.6

doi:10.1038/s41408-024-01044-4

Shadman, Mazyar; Tedeschi, Alessandra; Mohseninejad, Leyla; Yang, Keri; Lamanna, Nicole; Xu, Sheng; Cohen, Aileen; Challagulla, Swetha; Xue, Mei; Williams, Rhys; O'Brien, Susan M; Brown, Jennifer R; Tam, Constantine

Is CLL curable?

慢性淋巴细胞白血病可以治愈吗？

Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study

奥德罗内西他单药治疗CAR-T细胞疗法进展后的复发/难治性弥漫性大B细胞淋巴瘤：ELM-1研究的主要分析

Comparative efficacy of Bruton tyrosine kinase inhibitors in high-risk relapsed/refractory CLL: a network meta-analysis

布鲁顿酪氨酸激酶抑制剂在高危复发/难治性慢性淋巴细胞白血病中的疗效比较：一项网络荟萃分析

Acquired mutations in patients with relapsed/refractory CLL who progressed in the ALPINE study

ALPINE 研究中复发/难治性 CLL 患者获得性突变

Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912

E1912 研究中，接受伊布替尼治疗的 CLL 患者中，IGHV 突变状态与耐受性和长期疾病控制之间的关系

Real-world survival outcomes in first-line ibrutinib-treated patients with high-risk CLL/SLL

一线接受伊布替尼治疗的高危慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者的真实世界生存结果

Efficacy of zanubrutinib versus acalabrutinib for relapsed or refractory chronic lymphocytic leukemia (R/R CLL): a matching-adjusted indirect comparison (MAIC)

zanubrutinib 与 acalabrutinib 治疗复发或难治性慢性淋巴细胞白血病 (R/R CLL) 的疗效：匹配调整间接比较 (MAIC)

Composite chronic lymphocytic leukemia and mantle cell lymphoma involving the bone marrow: a case report and literature review

累及骨髓的复合型慢性淋巴细胞白血病和套细胞淋巴瘤：病例报告及文献综述

Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE

在复发/难治性慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者中，泽布替尼与伊布替尼的持续获益：ALPINE 研究的最终比较分析

Similar efficacy of ibrutinib arms across ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia: a matching-adjusted indirect comparison

在复发/难治性慢性淋巴细胞白血病的ALPINE和ELEVATE-RR试验中，伊布替尼各组的疗效相似：一项匹配调整的间接比较研究